Newsfeeds - Spark Newswire

5 minute read

Zealand Pharma Announces Directed Issue And Private Placement Of ~4.5M New Shares

Today, 6:33 AM

Company announcement – No. 43 / 2022 Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE

ZEAL

1 minute read

Zealand Pharma Announces Results From Phase 3 Trial Of Glepaglutide; Glepaglutide Treatment Met Primary Endpoint

By Benzinga Newsdesk

Today, 6:33 AM

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a

ZEAL

4 minute read

Zealand Pharma Announces Oral Presentation Of Phase 2 Data For BI 456906 At The 58th Annual Meeting Of The European Association For The Study of Diabetes September 21

By Benzinga Newsdesk

Today, 6:33 AM

Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) BI 456906

ZEAL

1 minute read

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels

By Vandana Singh

Today, 6:33 AM

Zealand Pharma A/S (NASDAQ:ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE:NVO) to commercialize Zegalogue (dasiglucagon) for…

NVO

1 minute read

Zealand Pharma Announced Global License and Development Agreement with Novo Nordisk for ZEGALOGUE; Zealand to Receive Upfront Payment of DKK 25M Plus Up to DKK 45M in Milestones

By Charles Gross

Today, 6:33 AM

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® (dasiglucagon) for injection.

NVO

8 minute read

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday

By Lisa Levin

Today, 6:33 AM

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

ACRX

6 minute read

Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 6:33 AM

Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.

ACRX

1 minute read

News

Zealand Pharma Announces Directed Issue And Private Placement Corresponding To Approx. 6.6 % Of Existing Share Capital

By Benzinga Newsdesk

Today, 6:33 AM

-SEC Filing

ZEAL

3 minute read

Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher

By Lisa Levin

Today, 6:33 AM

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Thursday.

BGXX

3 minute read

38 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 6:33 AM

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

AFI